Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton Sells 5,479 Shares

Bioventus Inc. (NYSE:BVS - Get Free Report) CFO Mark Leonard Singleton sold 5,479 shares of the business's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $9.79, for a total value of $53,639.41. Following the completion of the transaction, the chief financial officer now directly owns 131,963 shares in the company, valued at approximately $1,291,917.77. This represents a 3.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Mark Leonard Singleton also recently made the following trade(s):

• On Tuesday, February 18th, Mark Leonard Singleton sold 6,498 shares of Bioventus stock. The shares were sold at an average price of $10.19, for a total transaction of $66,214.62.

Bioventus Price Performance

Shares of Bioventus stock traded down $0.06 during trading hours on Friday, reaching $9.03. The company's stock had a trading volume of 251,471 shares, compared to its average volume of 431,244. The firm has a 50 day moving average price of $10.07 and a 200-day moving average price of $10.98. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The stock has a market cap of $739.95 million, a P/E ratio of -14.80 and a beta of 0.86. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38.

Institutional Investors Weigh In On Bioventus

Several large investors have recently added to or reduced their stakes in BVS. Charles Schwab Investment Management Inc. boosted its holdings in shares of Bioventus by 38.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company's stock worth $4,662,000 after purchasing an additional 109,359 shares during the period. Point72 Asset Management L.P. bought a new stake in Bioventus in the third quarter worth $788,000. JPMorgan Chase & Co. boosted its stake in Bioventus by 228.3% during the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company's stock worth $3,032,000 after buying an additional 176,442 shares during the period. State Street Corp increased its position in Bioventus by 38.8% during the third quarter. State Street Corp now owns 676,501 shares of the company's stock valued at $8,084,000 after acquiring an additional 189,216 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Bioventus by 7.5% in the third quarter. Geode Capital Management LLC now owns 940,496 shares of the company's stock valued at $11,241,000 after acquiring an additional 65,374 shares during the period. 62.94% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on BVS shares. Canaccord Genuity Group restated a "buy" rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, March 17th. JPMorgan Chase & Co. upgraded Bioventus from an "underweight" rating to a "neutral" rating and raised their price target for the company from $12.00 to $13.00 in a report on Tuesday, December 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.